Viewing nowPregabalin Capsule 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Eden Pharma Co., Ltd.

MFDS item code 201603621 · Approved 2016.06.20 · Insurance code 628900860
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunct to treat partial seizures, which is part of epilepsy, in adult patients. Additionally, it helps alleviate pain caused by fibromyalgia. It is effective in improving various neurological symptoms.
This medicine is administered orally, with or without food, as pregabalin in the total daily dose divided into 2 doses. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For females, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Administration is not recommended for children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.
This drug may increase the risk of suicidal thoughts or behavior; therefore, patients should consult a physician immediately if they experience depression or mood changes during treatment. Patients with allergies to the ingredients of this medication or with specific genetic problems such as lactose intolerance should not use it. Diabetes patients should be cautious as this medication may cause weight gain and requires careful blood sugar control. If symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients are at risk of falls due to dizziness or drowsiness when taking this medication, especially during the initial period of use. This drug may temporarily cause blurred vision or changes in eyesight; patients should report any abnormal symptoms to their physician. Sudden discontinuation of the medication may cause withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so the dosage should be gradually reduced according to the doctor's instructions. There is a risk of drug abuse; therefore, special caution is required for patients with a history of substance abuse when taking this medication. Patients with decreased kidney function may need dosage adjustments, and those with heart disease should use it with caution. Combining this medication with opioid analgesics may enhance central nervous system depressant effects, so caution is necessary. During early pregnancy, this medication may pose a risk to the fetus, and pregnant women should avoid taking it. Women of childbearing potential should use effective contraception. Lactating women should consult a physician or consider discontinuing breastfeeding, as this drug can be excreted in breast milk. It is advisable to avoid driving or operating machinery, as this medication may cause dizziness or drowsiness until symptoms are confirmed. This medication can cause severe skin reactions, so if a rash or swelling occurs, discontinue use immediately and consult a healthcare professional. In cases of overdose, confusion, drowsiness, depression, and seizures may occur, necessitating immediate hospital treatment for appropriate care. Keep this medication out of reach of children, and be cautious as transferring it to different containers may alter its quality.
Not everyone experiences these, and they can vary from person to person.
This medication can be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 15°C and 30°C to preserve the medication's effectiveness and safety.
A white powder contained in a hard capsule with white upper and lower parts that is white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Eden Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.